← Back to Journals

NATURE MEDICINE

Publisher:
ISSN:
Category:
Impact factor:

Feed status

8 parsed articles

Last update: 2026-09-21

Latest articles

Levetiracetam therapeutically targets GABAergic synapses in diffuse midline glioma

2026-09-17

Tara Barron, Richard Drexler, Aaron Mochizuki, Evan Cantor, Kiarash Shamardani, Pamelyn J. Woo, Neeraj Soni, Dana Tlais, Andrea Franson, Samantha Lyons, Truman Knowles, Shannon Raber, Vilina Mehta, Michael A. Quezada, Michael B. Keough, Samin Malaki Jahan, Linh Thuy Vo, Enrique Herrera Castañeda, Kathryn R. Taylor, Lijun Ni, Kim Kilian, Samuel H. Wu, Franz L. Ricklefs, Ulrich Schüller, Sabine Mueller, Paul G. Fisher, Cynthia J. Campen, Hannes Vogel, Sonia Partap, Kai Kaila, Carl Koschmann, Michelle Monje

Results of this study show in experimental models and data from patient cohorts that the antiseizure medication levetiracetam is associated with longer survival and reduced tumor growth in diffuse midline glioma, but not hemispheric high-grade glioma, by selectively dampening GABAergic synaptic signaling, independently of its canonical SV2A-mediated primary antiseizure mechanism.

DOI: 10.1038/s41591-026-04646-6

EBV reactivation priming of the peripheral immune system in multiple sclerosis relapse

2026-09-16

Devin A. King, Shrishti Saxena, Danielle Caefer, Kyle C. Downer, Laura E. Saucier, Ethan Goodman, Jonmichael Aracena, Alena Zhirova, Anthilia Alchanat, Saoirse Nolan, Hrishikesh Lokhande, Howard L. Weiner, Benjamin E. Gewurz, Tanuja Chitnis

Increased expression of EBV reactivation genes in B cells and MS risk genes targeted by the EBV protein EBNA-2 precedes MS attacks, linking EBV reactivation and genetic risk to the development of MS relapses.

DOI: 10.1038/s41591-026-04665-3

Factor IX Padua AAV gene therapy in adolescents with hemophilia B: a phase 1 trial

2026-09-16

Feng Xue, Ai Zhang, Mankai Ju, Xia Wu, Bingqi Xu, Xiaolei Pei, Yuhua Wang, Wei Liu, Aiguo Liu, Wei Jiang, Xinyue Dai, Yunfei Chen, Xiaofan Liu, Rongfeng Fu, Ting Sun, Wenjing Gu, Jing Zheng, Zengmin Du, Caifeng Yang, Xiao Xiao, Renchi Yang, Qun Hu, Lei Zhang

In this single-arm phase 1 trial, an AAV gene therapy carrying the Padua variant of factor IX was well tolerated in 11 adolescents with hemophilia B and led to reductions in annualized bleeding rate.

DOI: 10.1038/s41591-026-04636-8

Sex-specific biological aging clocks across organs and omics

2026-09-16

Zhiyuan Song, Derek Feng, Naowal Azraf Rahman, Michael R. Duggan, Qu Tian, Jian Zeng, Xia Zhou, Chunrui Zou, Michael S. Rafii, Li Shen, Paul Thompson, Eleanor M. Simonsick, Keenan A. Walker, Andrew Zalesky, Christos Davatzikos, Paul Aisen, Luigi Ferrucci, Susan M. Resnick, Junhao Wen

Sex-specific biological aging clocks across multiple organs and molecular systems show that female and male aging patterns can differ in organ-specific, disease-relevant ways.

DOI: 10.1038/s41591-026-04662-6

Liquid biopsy for early detection of pancreatic ductal adenocarcinoma

2026-09-16

Caiming Xu, Alessandro Mannucci, Haiyong Han, Ruben M. Munoz, Derek Cridebring, Sourat Darabi, Yuji Toiyama, Yoshinaga Okugawa, Gagandeep Singh, Mustafa Raoof, Joon Oh Park, James Lin, Gregory Idos, Michael J. Demeure, Erkut Borazanci, Douglas B. Evans, Susan Tsai, Eunsung Jun, Carlos Becerra, Scott A. Celinski, Laleh Melstrom, Vincent Chung, Guixin Zhang, Dong Shang, David L. Bartlett, Mitsuro Kanda, Song Cheol Kim, Valsamo Anagnastou, Giulia Martina Cavestro, John S. Bolton, Ali H. Zaidi, Daniel Von Hoff, Ajay Goel

In a prospective study involving 1,785 individuals from four countries, the PANXEON exosome-based biomarker, combined with carbohydrate antigen 19-9 levels, achieves high sensitivity for the detection of early-stage pancreatic cancer.

DOI: 10.1038/s41591-026-04625-x

Beyond the breakthrough for RAS-driven cancers

2026-09-15

Rich C. King, Erica S. Tsang, Jennifer J. Knox

Two early clinical studies of selective KRASG12D inhibitors show encouraging activity in advanced cancers with G12D mutations, signaling a transformative change in the treatment landscape for RAS-driven cancers with potential applications across tumor types and stages of disease.

DOI: 10.1038/s41591-026-04610-4